Some investors asked questions on the investor interactive platform: Hello, Secretary Dongcrashtwinsanity2, consult the following questionscrashtwinsanity2:1. Have your company obtained terbutaline sulfate solution for nebulized inhalation and other drugs on the market? What is the market share? 2. The country vigorously develops synthetic biotechnology. Does the company have synthetic biological products or technology reserves? thank
Huluwa (605199.SH) stated on the investor interactive platform on May 14 that the company obtained the "Drug Registration Certificate" approved and issued by the State Food and Drug Administration on April 23, 2024 for terbutaline sulfate solution for nebulized inhalation. No sales have yet been formed. There are currently no synthetic biological products or technical reserves.
(Article source: Daily Economic News)